Impax Reports Fourth Quarter and Full Year 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/13/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Impax Laboratories (IPXL) PT Lowered to $10 at RBC Capital
March 2, 2017 6:19 AM ESTRBC Capital lowered its price target on Impax Laboratories (NASDAQ: IPXL) to $10.00 (from $15.00) while maintaining a Sector Perform rating following results
Analyst Randall Stanicky commented, "The stock was down -35% following IPXL's 4Q results and first-time 2017 update (no revenue or EPS... More
Piper Jaffray Downgrades Impax Laboratories (IPXL) to Underweight
March 1, 2017 2:50 PM ESTPiper Jaffray downgraded Impax Laboratories (NASDAQ: IPXL) from Neutral to Underweight with a price target of $7.00.
For an analyst ratings summary and ratings history on Impax Laboratories click here. For more ratings news on Impax Laboratories click here.
Shares of Impax Laboratories closed at $14.25 yesterday.
... MoreImpax Laboratories (IPXL) Reports In-Line Q4 EPS
March 1, 2017 6:36 AM ESTImpax Laboratories (NASDAQ: IPXL) reported Q4 EPS of $0.16, in-line with the analyst estimate of $0.16. Revenue for the quarter came in at $198.4 million versus the consensus estimate of $219.25 million.
For earnings history and earnings-related data on Impax Laboratories (IPXL) click here.
... More